Table 4.
Clinical characteristics at biopsy and follow-up for patients with blood-stasis BC and non-blood-stasis BC.
| Characteristics | Blood-stasis BC (n=64) | Non- Blood-stasis BC (n=139) | P values |
|---|---|---|---|
| Age (years) | 39.6±10.4 | 40.3±12.1 | 0.689 |
| Male (n (%)) | 19 (29.7) | 92 (66.2) | 0.001 |
| BMI (kg/m2) | 24.5±4.3 | 24.4±3.4 | 0.955 |
| Smoking (n (%)) | 12(18.8) | 35(25.2) | 0.313 |
| Alcohol drinking (n (%)) | 14(21.9) | 28(20.1) | 0.777 |
| Less exercise (n (%)) | 14(21.9) | 38(27.3) | 0.407 |
| MAP(mmHg) | 98.5±13.1 | 98.0±13.3 | 0.819 |
| Urinary protein (g/d) | 1.92±1.70 | 1.56±1.49 | 0.144 |
| Serum albumin (g/L) | 37.0±5.8 | 39.4±5.7 | 0.008 |
| eGFR (ml/min) | 77.1±30.0 | 81.7±28.2 | 0.299 |
| Serum uric acid (μmol/L) | 410.5±118.7 | 369.3±89.0 | 0.007 |
| CKD stage (n (%)) | 0.739 | ||
| stage 1 | 25(39.1) | 63(45.3) | |
| stage 2 | 17(26.6) | 38(27.3) | |
| stage 3 | 19(29.7) | 34(24.5) | |
| stage 4 | 3(4.7) | 4(2.9) | |
| Treatment∗(n (%)) | 31(48.4) | 72(51.8) | 0.656 |
| Follow-up (months) | 64.8±17.3 | 63.6±15.6 | 0.624 |
| Endpoint event (n (%)) | 18(28.1) | 14(10.1) | 0.001 |
∗Corticosteroid and/or immunosuppressant treatments; BMI: body mass index; MAP: mean arterial pressure; eGFR: estimated glomerular filtration rate; CKD: chronic kidney disease; endpoint event: 50% decline in eGFR or end-stage renal disease.